Changes in Beneficial Ownership · 4
ZAI LAB LTD
ZAILFOTCEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-11
- Issuer
- Zai Lab Ltd
- Issuer CIK
- 0001704292
- Trading symbol
- ZLAB
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Chen Yajing
- Reporting owner CIK
- 0001985694
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| American Depositary Shares[F1] | 2026-08-11 | S · Form 4[F2] | 619 | D | 25.00 | 35,072 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.↩ 1
- F2
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.↩ 1
Signature 1
- Signed
- /s/ Bruce Blefeld, Attorney-in-Fact
- Date
- 2026-08-13
Company context
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.